BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCL

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Efficacy of pirtobrutinib in patients with R/R MCL previously treated with a covalent BTKiПодробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

BRUIN MCL-321: Pirtobrutinib in BTKi naïve MCLПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее

Latest updates from the Phase I/II BRUIN studyПодробнее

Phase I/II BRUIN update: efficacy of pirtobrutinib in R/R Waldenström's macroglobulinemiaПодробнее

Rebooting the BTK Inhibitor Sequence in MCLПодробнее

Selecting BTK inhibitors for patients with MCLПодробнее

BRUIN MCL-321: pirtobrutinib vs investigator choice of BTK inhibitor in BTK inhibitor-naive MCLПодробнее

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA – Dr. Wael AlanaziПодробнее

BTKI inhibitors in the treatment of B-cell lymphoma - Anthony Mato sessionПодробнее